PMC5519796_01
PMC5519796_02
PMC5519796_03
Case 2:volumetric MRI tumour measurements of perihepatic and pelvic mesothelioma demonstrating a 39% reduction in tumour volume after 10 months treatment with apitolisib.
esmoopen-2016-000101f01.jpg
PMC5519796_03_esmoopen-2016-000101f01.jpg
F1
Tumors (RECIST). The use of MRI volumetric assessment demonstrates a significant reduction of the large burden peritoneal disease by 39% (figure 1), highlighting the superiority of MRI imaging in this type of disease.